[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

651A.O3.6 Myeloma - Biology and Pathophysiology, excluding Therapy: Therapeutic potential of genetic and epigenetic targets in Multiple Myeloma

Oral and Poster Abstracts
Oral Session
Monday, December 7, 2009: 6:00 PM-7:30 PM
293-296 (Ernest N. Morial Convention Center)
Moderators:
Irene Ghobrial, M.D. and Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA
6:00 PM
Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents

Lia A. Moulopoulos1*, Evangelos Terpos2, Dimitrios Christoulas2*, Efstathios Kastritis2*, Dimitra Anagnostou3*, Andreas Koureas1*, Maria Roussou2*, Maria Gavriatopoulou2*, Magdalini Migkou2*, Marina Iakovaki2*, Maria Gkotzamanidou2*, Vasilios Skiadas1*, Anna Tasidou3* and Meletios A. Dimopoulos2

1Department of Radiology, University of Athens School of Medicine, Athens, Greece
2Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
3Department of Hemopathology, Evangelismos General Hospital, Athens, Greece

6:15 PM
Increased Osteocyte Apoptosis in Multiple Myeloma Patients: A Potential Role in Bone Remodeling Alterations Related to Osteolytic Bone Lesions

Nicola Giuliani1, Marzia Ferretti2*, Manuela Abeltino1*, Cristina Mancini3*, Eugenia Martella3*, Benedetta Dalla Palma1*, Marina Bolzoni1*, Valentina Sgobba1*, Paola Storti1*, Vittorio Rizzoli1 and Carla Palumbo2*

1Unit of Hematology and BMT, University of Parma, Parma, Italy
2Dipartimento di Anatomia e Istologia Sezione di Anatomia Umana, University of Modena, Modena, Italy
3Pathology, University of Parma, Parma, Italy

6:30 PM
Analysis of PKB/Akt-Signaling and Oncogenic Ras in Multiple Myeloma

Torsten Steinbrunn1*, Thorsten Stühmer1*, Manik Chatterjee1*, Stefan Gattenlöhner2* and Ralf C Bargou1

1Department of Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany
2Institute of Pathology, University Hospital Würzburg, Würzburg, Germany

6:45 PM
HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma

Michael A Chapman1, Jean-Philippe Brunet1*, Jonathan J Keats, PhD2, Angela Baker3*, Mazhar Adli4*, Anna C. Schinzel5*, Gregory Ahmann, BS2, Harview Christina1*, Anna Moore3*, Vijayalakshmi Shanmugam3*, Louise M. Perkins, PhD6, Daniel Auclair, PhD6*, William C. Hahn, MD, PhD5*, Bradley E. Bernstein, MD4*, Leif Bergsagel2*, Rafael Fonseca2*, John Carpten3*, Jeffrey Trent3* and Todd R. Golub, MD1

1Broad Institute, Cambridge, MA
2Mayo Clinic Scottsdale, Scottsdale, AZ
3Translational Genomics Research Institute, Phoenix, AZ
4Massachusetts General Hospital and Harvard Medical School, Charlestown, MA
5Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
6Multiple Myeloma Research Foundation, Norwalk, CT

7:00 PM
Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in  Myeloma in Vitro and In Vivo

Sophia Adamia1, Mariateresa Fulciniti2*, Herve Avet-Loiseau3*, Samir B Amin, MBBS4*, Parantu Shah, PhD5*, Daniel Ruben Carrasco, M.D., Ph.D.6*, Stephane Minvielle7*, Philippe Moreau, MD8*, Kenneth C. Anderson9 and Nikhil C. Munshi4

1Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Center Hospitalier Universitaire de Nantes, Nantes, France
4Medical Oncology, Dana-Farber Cancer Institute, Boston VA Healthcare System, Harvard Medical School, Boston, MA
5Department of Biostatistics and Department of Biostatistics and Computational Biology, Harvard School of Public Health and Dana-Farber Cancer Institute, Boston
6Medical Oncology, Dana Farber Cancer Institute, Boston, MA
7Laboratoire d'hématologie, CHU Nantes, Nantes, France
8University Hospital, Nantes, France
9Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

7:15 PM
MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis

Wee-Joo Chng, MD1, Gaofeng Huang2*, Siok-Bian Ng3*, Marta Chesi, PhD4*, Leif Bergsagel5* and Rafael Fonseca6*

1Dept. of Medicine, Yong Loo Lin School of Medicine, National Univ. of Singapore, Singapore, Singapore
2Haematology-Oncology, National University Hospital, Singapore, Singapore
3Pathology, National University Health System, Singaproe, Singapore
4Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ
5Mayo Clinic Scottsdale, Scottsdale, AZ
6Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ

*signifies non-member of ASH